All of our existing therapies for Pulmonary Arterial Hypertension act by vasodilation or relaxing blood vessels.  The current medications fall into one of three basic classes: 1.    PDE5 inhibitor a. Sildenafil (Revatio/Viagra) b. Tadalafil (Adcirca/Cialiis) c. Riociguat (Adempas—not truly a PDE5inhibitor but similar action) 2.    ERA a. Ambrisentan (Letairis) b. … [Read more...]

Clinical trials are essential to improving the care of PAH patients. These clinical trials allow us to determine if new medicines are safe and effective. Clinical trials also allow us to make improvements to existing treatments. For example, we are eagerly awaiting the approval of the implanted pump for intravenous Remodulin. Another example of a company that is trying to … [Read more...]

On December 22, 2017, after eight years of study, the FDA has finally granted pre-market approval (PMA) to the fully implantable system for Remodulin.  This groundbreaking pump and catheter system allows patients to benefit from Remodulin while minimizing the inconvenience and risks associated with having an external intravenous catheter. However, this does not mean that the … [Read more...]

  Assistance Now Available. Where to get financial assistance for the very expensive drugs used to treat Pulmonary Arterial Hypertension remains a hot topic. With an average treatment cost of around $100,000 per PAH patient per year, financial assistance is in great demand. Pulmonary Hypertension patients that are uninsured or privately insured have options for financial … [Read more...]

2017 is now behind us.  As 2018 begins there are some major changes in the landscape for patient assistance.  For many years Caring Voices Coalition has been a leader in assisting patients with their expensive medications.  However, this chapter is closing and we do not expect Caring Voices to participate in patient assistance going forward.  This has left many Pulmonary … [Read more...]